RACHEL FROEHLICH: Open Payments
NPI 1538393988 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$774 in 34 payments from 18 companies in 2025. Trend: 2023 $468 · 2024 $564 · 2025 $774
Food & beverage: $774
| Company | Payments | Amount |
|---|---|---|
| SANOFI-AVENTIS U.S. LLC | 8 | $224 |
| Chiesi USA, Inc. | 3 | $68 |
| Ascendis Pharma Endocrinology Inc | 3 | $67 |
| PFIZER INC. | 3 | $61 |
| Amgen Inc. | 2 | $46 |
| Lilly USA, LLC | 2 | $40 |
| Novo Nordisk Inc | 2 | $35 |
| Neurocrine BioSciences, Inc. | 1 | $30 |
| Soleno Therapeutics, Inc. | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $25 |
Products named: TZIELD, MYCAPSSA, Yorvipath, SOMAVERT, MOUNJARO, Ozempic, CRENESSITY, VYKAT XR.
Industry payments across MD — which companies pay providers there.
